RedHill Biopharma announced that its partner, Gaelan Medical, a wholly owned subsidiary of the Ghassan Aboud Group, has received marketing approval from the United Arab Emirates Ministry of Health for Talicia. The approval makes Talicia the first approved rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDHL:
- RedHill Biopharma: RHB-107 included in Government-supported COVID-19 trial
- RedHill Biopharma announces registered direct offering, warrant exercise
- RedHill Biopharma announces U.S. government funding for Opaganib development
- Biotech Alert: Searches spiking for these stocks today
- RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights